Raras
Buscar doenças, sintomas, genes...
Dermatose tóxica
ORPHA:293815DOENÇA RARA

Necrólise epidérmica tóxica (NET) ou Síndrome de Lyell é um tipo de reação adversa cutânea grave que afeta mais de 30% da pele. Começa com sintomas de gripe e alguns dias depois, aparecem vesículas e descamação dolorosa em áreas da pele ou das membranas mucosas, como a boca. As complicações incluem a desidratação, sepse, pneumonia e falência de múltiplos órgãos. A síndrome de Stevens–Johnson (SJS) é muito similar, mas afeta menos de 10% da pele. Uma forma intermédia NET/SJS afeta entre 10 e 30% da pele.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Dermatose tóxica é uma doença rara associada a genes como HLA-B e IKZF1, manifestando-se com bolhas genitais, edema facial, secura vaginal e uveíte anterior. Pode apresentar calafrios, simbléfaro, vulvodinia e alterações na faringe, com leucocitose associada.

Medicamentos
10 registrados
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE, CORTISONE ACETATE

Tem tratamento?

10 medicamentos registrados
Ver detalhes, fases e interações →
DEXAMETHASONE SODIUM PHOSPHATEDEXAMETHASONECORTISONE ACETATEPREDNISONEETANERCEPTCYCLOSPORINEINFLIXIMABPALIFERMINTOFACITINIBABROCITINIB
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
16 sintomas
🧬
Pele e cabelo
14 sintomas
🩸
Sangue
12 sintomas
🫁
Pulmão
11 sintomas
👁️
Olhos
8 sintomas
🫘
Rins
6 sintomas

+ 51 sintomas em outras categorias

Características mais comuns

Bolhas genitais
Edema facial
Secura vaginal
Leucocitose
Uveíte anterior
Anormalidade da vagina
136sintomas
Sem dados (136)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 136 características clínicas mais associadas, ordenadas por frequência.

Bolhas genitaisGenital blistering
Edema facialFacial edema
Secura vaginalVaginal dryness
LeucocitoseLeukocytosis
Uveíte anteriorAnterior uveitis

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Últimos 10 anos200publicações
Pico2026193 papers
Linha do tempo
2026Hoje · 2026🧪 1995Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição.

Not applicable
HLA-BHLA class I histocompatibility antigen, B alpha chainCandidate gene tested inTolerante
FUNÇÃO

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:23209413, PubMed:25808313, PubMed:29531227, PubMed:9620674). May also present self-peptides derived from the

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
E3 ubiquitin ligases ubiquitinate target proteins
MECANISMO DE DOENÇA

Stevens-Johnson syndrome

A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
8283.6 TPM
Baço
6025.1 TPM
Linfócitos
5071.2 TPM
Pulmão
4631.0 TPM
Intestino delgado
2873.0 TPM
OUTRAS DOENÇAS (7)
obsolete pulmonary arterial hypertension associated with connective tissue diseaseTakayasu arteritistemporal arteritisStevens-Johnson syndrome
HGNC:4932UniProt:P01889
IKZF1DNA-binding protein IkarosCandidate gene tested inAltamente restrito
FUNÇÃO

Transcription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
NOTCH3 Intracellular Domain Regulates Transcription
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
34.6 TPM
Sangue
30.1 TPM
Linfócitos
21.4 TPM
Intestino delgado
11.1 TPM
Pulmão
10.5 TPM
OUTRAS DOENÇAS (3)
pancytopenia due to IKZF1 mutationsStevens-Johnson syndromeB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
HGNC:13176UniProt:Q13422
HLA-AHLA class I histocompatibility antigen, A alpha chainCandidate gene tested inTolerante
FUNÇÃO

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:10449296, PubMed:12138174, PubMed:12393434, PubMed:1402688, PubMed:15893615, PubMed:17189421, PubMed:19543285

LOCALIZAÇÃO

Cell membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
E3 ubiquitin ligases ubiquitinate target proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
3020.0 TPM
Linfócitos
2770.5 TPM
Baço
2431.7 TPM
Pulmão
1955.9 TPM
Intestino delgado
1462.0 TPM
OUTRAS DOENÇAS (2)
birdshot chorioretinopathyStevens-Johnson syndrome
HGNC:4931UniProt:P04439

Medicamentos e terapias

DEXAMETHASONE SODIUM PHOSPHATEPhase 4

Mecanismo: Glucocorticoid receptor agonist

DEXAMETHASONEPhase 4

Mecanismo: Glucocorticoid receptor agonist

CORTISONE ACETATEPhase 4

Mecanismo: Glucocorticoid receptor agonist

PREDNISONEPhase 4

Mecanismo: Glucocorticoid receptor agonist

ETANERCEPTPhase 3

Mecanismo: TNF-alpha inhibitor

CYCLOSPORINEPhase 3

Mecanismo: Cyclophilin A modulator

INFLIXIMABPhase 2

Mecanismo: TNF-alpha inhibitor

PALIFERMINPhase 1

Mecanismo: Fibroblast growth factor receptor 2 agonist

TOFACITINIBPhase 0.5

Mecanismo: Janus Kinase (JAK) inhibitor

ABROCITINIBPhase 0.5

Mecanismo: Tyrosine-protein kinase JAK1 inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

108 variantes patogênicas registradas no ClinVar.

🧬 HLA-B: GRCh37/hg19 6p21.33(chr6:30944923-31867966)x1 ()
🧬 HLA-B: NM_005514.8(HLA-B):c.299A>T (p.Glu100Val) ()
🧬 HLA-B: NM_005514.8(HLA-B):c.1011A>T (p.Ser337=) ()
🧬 HLA-B: NM_005514.8(HLA-B):c.*4+35C>G ()
🧬 HLA-B: NM_005514.8(HLA-B):c.*4+47T>A ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado5
3Fase 33
2Fase 21
1Fase 11
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 10 medicamentos · 5 ensaios
✓ Aprovados — podem ser usados hoje
DEXAMETHASONE SODIUM PHOSPHATEDEXAMETHASONECORTISONE ACETATEPREDNISONE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Dermatose tóxica

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

0 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥉Melhor nível de evidência: Relato de caso
Timeline de publicações
0 papers (10 anos)
#1

Autologous stem cell transplant for severe, progressive juvenile systemic sclerosis.

Stem cells translational medicine2026 Mar 23

A esclerose sistêmica juvenil (jSSc) é uma doença autoimune rara e grave em crianças e adolescentes, causando espessamento da pele e danos a órgãos, com opções de tratamento atualmente limitadas. Este artigo relata um caso promissor onde o transplante autólogo de células-tronco foi associado à melhora clínica significativa em um jovem de 17 anos com jSSc refratária, sugerindo um potencial novo caminho terapêutico para casos graves que não respondem aos tratamentos convencionais.

🇧🇷 traduzido
#2

Antimicrobial Peptides: Structure, Mechanisms, and Therapeutic Potential in Combating Infectious Diseases.

Current protein & peptide science2026 Mar 16

Os Peptídeos Antimicrobianos (AMPs) são moléculas naturais com potencial terapêutico contra uma vasta gama de infecções causadas por bactérias, vírus e fungos, oferecendo uma alternativa crucial aos antibióticos tradicionais devido à crescente resistência. Para pacientes e médicos, os AMPs são relevantes por sua capacidade única de atacar patógenos de múltiplas formas e modular a resposta imune, sendo investigados para diversas aplicações, como o tratamento de infecções de pele, doenças respiratórias e sepse. Embora alguns já estejam no mercado ou em testes clínicos, a pesquisa atual busca superar desafios como estabilidade e toxicidade para otimizar seu uso como terapias anti-infecciosas da próxima geração.

🇧🇷 traduzido
#3

Erosive pustular dermatosis-like scalp reaction following cranial radiotherapy in a patient with EGFR-mutant NSCLC treated with amivantamab.

Oncoscience2026

Amivantamab, um tratamento crescente para um tipo de câncer de pulmão, é conhecido por causar efeitos cutâneos. Este artigo descreve um novo e importante: uma reação grave no couro cabeludo, semelhante à dermatose pustulosa erosiva, que surge especificamente em áreas que já foram submetidas à radioterapia cranial. É crucial que médicos e pacientes reconheçam estas lesões no couro cabeludo como um possível efeito adverso do amivantamab, especialmente na presença de radioterapia prévia ou concomitante, pois esta reação não havia sido identificada nos ensaios clínicos.

🇧🇷 traduzido
#4

Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients Receiving Combination Therapy of Candesartan and Carvedilol for Primary Prevention: A Prospective Longitudinal Study.

Journal of Korean medical science2026 Mar 16

O título da sua pergunta menciona "Toxic dermatosis", mas o artigo científico fornecido é sobre "Cancer Therapy-Related Cardiac Dysfunction". Vou resumir o artigo fornecido sobre disfunção cardíaca. **Resumo para Pacientes e Médicos:** Este estudo demonstrou que, mesmo com uma estratégia de prevenção primária combinando candesartana e carvedilol, a disfunção cardíaca assintomática relacionada à terapia do câncer (CTRCD) ainda é comum em pacientes com câncer de mama (24,6% de incidência), embora a maioria dos casos seja leve. Para pacientes e médicos, a mensagem principal é que a hipertensão arterial é um fator de risco significativo e independente para o desenvolvimento de CTRCD, especialmente naqueles que recebem terapias cardiotóxicas, reforçando a importância do seu controle rigoroso.

🇧🇷 traduzido
#5

Out of Nucleus: Serine 727 Phosphorylation Orchestrates Non-Canonical STAT3 Functions-Relevance to Triple-Negative Breast Cancer.

International journal of molecular sciences2026 Feb 27

Este artigo destaca que, no câncer de mama triplo-negativo (CMTN), a ativação da proteína STAT3 é crucial para a progressão e resistência aos tratamentos. Embora as abordagens terapêuticas tradicionais se concentrem na fosforilação de tirosina 705 (p-Y705), a fosforilação de serina 727 (p-S727) emerge como um mecanismo distinto que impulsiona funções não-canônicas do STAT3 fora do núcleo, mantendo a doença mesmo quando a p-Y705 é inibida. Para pacientes e médicos, isso significa que novas estratégias terapêuticas que visem especificamente a p-S727, ou combinem o bloqueio de p-Y705 e p-S727, podem ser mais eficazes para superar a resistência e melhorar os resultados no CMTN. Integrar o entendimento dessas duas vias na estratificação de pacientes pode levar a tratamentos mais personalizados, com maior eficácia e menor toxicidade.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 200

2026

In silico designing of palbociclib loaded PLGA long-acting intramuscular injection for palliative therapy of HR+/HER2- metastatic breast cancer.

The Journal of pharmacy and pharmacology
2026

Thermoradiotherapy-Driven Enhancement of Cuproptosis by Copper-Nitroimidazole Based Nanoparticles.

International journal of nanomedicine
2026

Doxycycline-Induced Phototoxicity Localized to Vitiligo-Affected and Sun-Exposed Skin.

Cureus
2026

Autologous stem cell transplant for severe, progressive juvenile systemic sclerosis.

Stem cells translational medicine
2026

Investigating the mechanistic link between pesticide DDT and breast cancer through network toxicology, molecular docking, and molecular dynamics simulation.

Scientific reports
2026

The expanding role of biocompatible hydrogels in plant-derived exosome-like nanovesicles for skin diseases: prospects and challenges.

Annals of medicine
2026

Antimicrobial Peptides: Structure, Mechanisms, and Therapeutic Potential in Combating Infectious Diseases.

Current protein & peptide science
2026

Mechanistic insights into the roles of astragalosides and Astragalus polysaccharides in gynecological and breast cancers (Review).

Oncology reports
2026

A Rash Decision: Mycoplasma-Induced Mucositis in a Young Adult.

Cureus
2026

Erosive pustular dermatosis-like scalp reaction following cranial radiotherapy in a patient with EGFR-mutant NSCLC treated with amivantamab.

Oncoscience
2026

Combinatorial Anti-Mitotic Activity of Loratadine/5-Fluorouracil Loaded Zein Tannic Acid Nanoparticles in Breast Cancer Therapy: In silico, in vitro and Cell Studies.

International journal of nanomedicine
2026

Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review.

International journal of nanomedicine
2026

Outcomes of CDK4/6 Inhibitor-Based Therapy in Premenopausal HR+/HER2- Metastatic Breast Cancer: Real World Data From A Multicenter Study.

Pharmacotherapy
2026

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Breast cancer research and treatment
2026

Nanoformulations of essential oils for the treatment of fungal diseases, with a focus on dermatophytes.

Archives of microbiology
2026

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.

Breast cancer research and treatment
2026

Potential acute hepatic injury in 2 cats exposed to topical human diclofenac.

The Canadian veterinary journal = La revue veterinaire canadienne
2026

Sintilimab-induced toxic epidermal necrolysis complicated in advanced gastric cancer: a case report and literature review.

Frontiers in immunology
2026

Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients Receiving Combination Therapy of Candesartan and Carvedilol for Primary Prevention: A Prospective Longitudinal Study.

Journal of Korean medical science
2026

Metamifop-induced human breast cancer cells proliferation: Revealing a proliferation mechanism distinct from 17β-estradiol.

Pesticide biochemistry and physiology
2026

ATOJIN: A Natural Products Mixture, Alleviates Atopic Dermatitis in DNCB-Induced NC/Nga Mice.

Mediators of inflammation
2026

Out of Nucleus: Serine 727 Phosphorylation Orchestrates Non-Canonical STAT3 Functions-Relevance to Triple-Negative Breast Cancer.

International journal of molecular sciences
2026

The Future of Breast Cancer Treatment: From Conventional Wisdom to Nanotechnology-Enabled Precision.

International journal of molecular sciences
2026

Clinical Outcomes of Dual-Beam Particle Therapy in Head and Neck Adenoid Cystic Carcinoma.

Cancers
2026

Association between time to treatment and financial toxicity among women with breast cancer in Ethiopia: a multicentre study in a low-resource setting.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2026

Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis.

Pediatric blood & cancer
2026

A Comparative Study of Oral Tofacitinib and Oral Methotrexate in the Treatment of Patients With Moderate to Severe Chronic Plaque Psoriasis.

Cureus
2026

Beyond the Target: Re-Emergence of Mycoplasma pneumoniae Supports Reclassification of Adult Mucocutaneous Eruptions.

International journal of dermatology
2026

[Very accelerated partial breast irradiation (VAPBI) with high-dose-rate interstitial brachytherapy following breast- conserving surgery of low-risk breast cancer patients].

Magyar onkologia
2026

PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis.

The oncologist
2026

SIRT1 regulates dermal fibroblast senescence via impaired deacetylase function and mitochondrial dysfunction during skin aging induced by chronic oral cadmium exposure.

Frontiers in public health
2026

Financial Hardship and Unhealthy Lifestyles: Perspectives and Solutions From Breast Cancer Survivors and Their Care Teams.

Cancer control : journal of the Moffitt Cancer Center
2026

Clarithromycin-based therapy with adjunctive photobiomodulation and microwave treatment for cutaneous Mycobacterium marinum infection.

Photodiagnosis and photodynamic therapy
2026

Dosimetric comparison study of ultrahypofractionated photon versus proton treatment plans in post breast-conserving surgery breast cancer.

PloS one
2026

The landscape of chemotherapy modifications among women treated for stage I-IIIA breast cancer.

Cancer
2026

In Situ Needle-Free Injection of Multiretention Micelles for Melanoma Therapy with Multiomics Insights into Tumor Targeting and Immune Modulation.

ACS nano
2026

Financial Toxicity in Patients With Breast Cancer Treated at Private Medicine Institutions in Brazil.

Cancer medicine
2026

Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.

AAPS PharmSciTech
2026

SEVERE TOXIC EPIDERMAL NECROLYSIS COMPLICATED BY ACUTE KIDNEY INJURY: DIAGNOSTIC AND THERAPEUTIC CONSIDERATIONS.

Georgian medical news
2026

A multi-target combinatorial therapy of MDBA alleviates atopic dermatitis via synchronized immunosuppression and barrier repair.

European journal of pharmacology
2026

Topical and systemic corticosteroids in the modern Management of Atopic Eczema: A scoping review.

International immunopharmacology
2026

Elevated phthalate exposure and metabolic susceptibility increased breast cancer risk: A 20-y follow-up study in Taiwan.

Proceedings of the National Academy of Sciences of the United States of America
2026

Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.

PloS one
2026

The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study.

Pharmacotherapy
2026

Melatonin inhibits FAK signaling to suppress PD-L1 expression and enhance chemosensitivity in triple-negative breast cancer.

International journal of medical sciences
2025

Clinical outcomes and safety study of CDK4/6 inhibitors in hormone-positive metastatic breast cancer - A real-world tertiary cancer center experience.

Indian journal of cancer
2026

miR-338-3p promotes radiation recall like dermatitis by suppressing pleiotrophin via the PI3K/Akt/Bcl2 pathway.

Molecular biomedicine
2026

Hyaluronic acid-based reduction responsive nanoparticles for Improved anti-psoriasis effects of traditional Chinese herb monomer oleanolic acid via blocking YAP-AREG axis.

Journal of nanobiotechnology
2026

Nitenpyram promotes breast cancer progression via PARP1: Integration of multi-omics analyses with experimental validation.

Ecotoxicology and environmental safety
2026

A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis.

Breast cancer research and treatment
2026

B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy.

Oncoimmunology
2026

Unraveling the therapeutic potential of Elaeagnus angustifolia extract on triple-negative breast cancer (TNBC): An investigation using zebrafish model.

PloS one
2026

Antimicrobial, anti-inflammatory, and antioxidant effect of onion peel extract (Allium cepa L.) on periodontal pathogen Porphyromonas gingivalis: An in vitro analysis.

Medicine
2026

An integrative analysis reveals the mechanism of plastic stabilizers inducing breast cancer.

PLoS computational biology
2026

Health risk analysis of micro-and nanoplastic exposure via the microbiota-gut-brain axis.

Frontiers in immunology
2026

Chitosan-functionalized Cu-doped NiO/reduced graphene oxide nanocarrier for pH-triggered delivery of 5-fluorouracil in breast cancer cells.

International journal of biological macromolecules
2026

Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Oncology
2026

Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer.

Breast (Edinburgh, Scotland)
2026

ABCC1 protects skin dendritic cells from FITC-induced toxicity by efflux and extracellular glutathione buffering.

Proceedings of the National Academy of Sciences of the United States of America
2026

A Stretchable, Transparent, Photothermally Stimulated Laser-Induced Graphene Patch for Noninvasive Skin Tumor Treatment.

ACS nano
2026

Occupational exposure to wood dust - legal aspects and preventive strategies.

Medycyna pracy
2026

[Toxic Epidermal Necrolysis: Study of an 81-case Series].

Annals of burns and fire disasters
2025

Comparative Outcomes of Doxorubicin and Cyclophosphamide with Sequential versus Concurrent Paclitaxel in the Adjuvant Treatment of Non-Metastatic Breast Cancer: A Cross-Sectional Analytical Study.

JNMA; journal of the Nepal Medical Association
2026

Recyclable Polymerizable Deep Eutectic Solvent-Based Three-Dimensional-Printed Dissolving Microneedles with pH-Responsive Delivery of ZIF-8-Loaded Minoxidil for Hair Loss Therapy.

ACS applied materials & interfaces
2026

Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.

Journal of drugs in dermatology : JDD
2026

Isoxazole derivatives as multi-target agents: virucidal, antibacterial, and antiproliferative effects on skin cancer cells.

Pharmacological reports : PR
2026

Harnessing nature: a systematic exploration of in vitro antileishmanial and antihuman African trypanosomal properties in traditional medicinal plants and their active principles.

Pharmaceutical biology
2026

Prediction of antibiotic-associated cutaneous adverse drug reactions using electronic health record foundation models.

NPJ digital medicine
2026

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

Journal for immunotherapy of cancer
2026

A natural product-hybridization approach toward anticancer drug discovery: synthesis and antitumor evaluation of CTBC6, designed from sulforaphane and magnolol.

Bioorganic chemistry
2026

Bismuthene-Based Nanoplatform for Synergistic Thermogenetic CRISPR and Photothermal Cancer Therapy.

Nano letters
2026

Piperine-induced AMPK activation and cell cycle arrest: insights from molecular simulations and experimental validation in breast cancer.

Medical oncology (Northwood, London, England)
2026

Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Si-Jun-Zi-Tang potentiates temozolomide's anti-melanoma efficacy and reduces its hepatotoxicity.

Phytomedicine : international journal of phytotherapy and phytopharmacology
2026

Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens.

Microbiology (Reading, England)
2026

Soluble Fas Ligand, an overlooked target of therapy in dermatological and non-dermatological conditions.

The Journal of dermatological treatment
2025

Impact of Green-Synthesized Silver Nanoparticle in Wistar Rats: Behavioral, Biochemical, And Histopathological Insights from Acute and Sub-Acute Oral Exposure.

Archives of Razi Institute
2025

Screening and Docking Molecular Studies of Natural Products Targeting overexpressed Receptors HER-2 in Breast Cancer.

Archives of Razi Institute
2026

Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma.

Frontiers in immunology
2026

A rare drug reaction: Toxic epidermal necrolysis following polymyxin B administration in a post-Bentall procedure.

Indian journal of pharmacology
2026

Rare manifestation of paclitaxel-induced cardiotoxicity: A case of restrictive cardiomyopathy in an elderly breast cancer patient.

Indian journal of pharmacology
2026

Rational Design and Characterization of 5-Fluorouracil-Loaded Lipid-Polymer Hybrid Nanoparticles for Enhanced Transdermal Delivery in Skin Cancer Therapy.

Drug development research
2026

Allogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: excellent outcomes with a reduced intensity, posttransplantation cyclophosphamide-based approach.

The Journal of allergy and clinical immunology
2026

Design and synthesis of c-Met/PARP dual-target inhibitors for the treatment of BRCA wild-type TNBC.

European journal of medicinal chemistry
2026

Secondary Exposure to IMQ or Irritants Enhances Psoriasiform Recurrence Through Inflammatory Memory.

Inflammation
2026

Skin toxicity of liquid crystal monomers (LCMs): Mitochondrial dysfunction and metabolic dysregulation revealed by integrated multi-omics analysis.

Ecotoxicology and environmental safety
2026

Tolerance and Outcomes of Partial Breast Radiation in a Community-based Setting.

Anticancer research
2026

Selective activation of pro-anti-CTLA-4 antibody maintains therapeutic efficacy and reduces immune-related adverse events.

International journal of biological macromolecules
2026

Targeting the transferrin receptor in breast cancer: nanotechnology-based drug delivery strategies.

Nanomedicine (London, England)
2026

[The concept of futility in medicine].

Revue medicale suisse
2026

Research Progress in Traditional Chinese Medicine for the Treatment of Breast Cancer.

The American journal of Chinese medicine
2026

Computational and Experimental Analysis of Sophora alopecuroides L. Chloroform Fraction: Active Components and Anti-Breast Cancer Resistance Mechanisms.

Molecules (Basel, Switzerland)
2026

Self-Assembled Berberine-Sinapic Acid Nanomedicine for Synergistic Chemotherapy.

Molecules (Basel, Switzerland)
2026

Investigating the In Vitro Mitochondria-Mediated Anticancer Activity of the Plant Metabolite Ursolic Acid.

International journal of molecular sciences
2026

A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence.

International journal of molecular sciences
2026

The Combination of Thymoquinone and Chloroquine Dose-Dependently Regulates Autophagy and Potentiates Metastatic Melanoma Cell Death via Autophagy-Dependent and -Independent Mechanisms.

International journal of molecular sciences
2026

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

European journal of cancer (Oxford, England : 1990)
2026

A Near-Infrared Emitting Aggregation-Induced Emission Photosensitizer with Endoplasmic Reticulum Targeting Ability for Breast Cancer Photodynamic Therapy.

ACS applied materials & interfaces
2026

Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer.

Current oncology (Toronto, Ont.)
2026

A Perplexing Plexopathy After Pembrolizumab Therapy in Early-Stage Triple-Negative Breast Cancer.

Current oncology (Toronto, Ont.)
2026

ROS-Activated Peptide-Based Prodrug for Chemoselective Covalent Targeting in Cancer Cells.

Journal of medicinal chemistry
2026

Phenylboronic acid functionalized resveratrol-based nanomedicines with enhanced targeting for synergistic chemo-photothermal breast cancer therapy.

Journal of materials chemistry. B
2026

The Anti-Aging Benefits of Phytoestrogens: Insights and Evidence.

Current medicinal chemistry
2026

Stevens-Johnson syndrome/toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer: A case report.

Medicine
2026

Role of laser therapy in enhancing chemotherapy efficiency in breast cancer: low level laser therapy, photochemotherapy, and photodynamic therapy as promising treatments.

Lasers in medical science
2026

Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics.

Cancer letters
2026

Ovarian function suppression decision-making and uptake in premenopausal women with breast cancer: a mixed methods analysis.

Breast cancer research and treatment
2026

Engineered Exosomes Co-Delivering EGF and FGF Ameliorate Androgenetic Alopecia in a Mouse Model.

International journal of nanomedicine
2025

Silver sulfadiazine in modern dermatology.

Dermatology online journal
2026

Role of Odour Perception in Health and Disease.

The European journal of neuroscience
2026

Induction of allergic dermatitis with dinitrofluorobenzene in Yama mice.

Methods in cell biology
2026

Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study.

European journal of cancer (Oxford, England : 1990)
2026

"Self" signal-suppressed metal-organic framework (MOF) nanodrug for enhanced immunotherapy of melanoma via CD47 blockade.

Colloids and surfaces. B, Biointerfaces
2026

Topical application of Clostridium butyricum by an anaerobic hydrogel for accelerated diabetic wound healing through selective bacteria inhibition and ROS scavenging.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
2026

Environmental benzophenone exposure promotes breast cancer cell metastasis via the Wnt/β-catenin pathway.

Journal of hazardous materials
2026

Novel platinum(IV) complexes trigger apoptosis and ferroptosis to conquer cisplatin resistance in triple-negative breast cancer.

Bioorganic chemistry
2026

An Injectable Thermosensitive Hydrogel Codelivering Permeability-Promoting Nintedanib-loaded Phase-transition Nanoparticles and Doxorubicin to Potentiate Immunogenic Cell Death in Triple-Negative Breast Cancer for Chemoimmunotherapy.

ACS applied materials & interfaces
2026

Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis.

Clinical breast cancer
2026

Environmentally relevant levels of BDE-209 induces proteomic and phosphoproteomic reprogramming in murine melanoma cells.

Chemosphere
2026

Aging-associated differences in mammary tumor-initiating populations and immune evasion pathways in breast cancer.

Proceedings of the National Academy of Sciences of the United States of America
2026

Adjuvant pegylated liposomal doxorubicin versus epirubicin sequential paclitaxel in triple-negative breast cancer: comparable efficacy with a distinct safety profile.

Frontiers in immunology
2026

Fufang Baizhi tincture protects melanocytes from oxidative stress by targeting CASP7-mediated apoptosis and EP300-associated transcriptional regulation.

Journal of ethnopharmacology
2026

MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.

The Lancet. Oncology
2026

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.

European journal of cancer (Oxford, England : 1990)
2026

Novel therapeutic topical gel approach for chronic inflammation and pain management in osteo- and viral-arthritis.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2026

Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials.

Expert opinion on biological therapy
2026

Homologous Tumor Cell-Derived Delivery of Doxorubicin via Liquid Nitrogen-Treated 4T1 Cells for Targeted Breast Cancer Therapy.

Molecular pharmaceutics
2026

Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer.

ACS biomaterials science & engineering
2026

Potential association between endocrine disrupting chemicals (EDCs) and gynecomastia: a systematic review based on partial experimental evidenceendocrine-disrupting chemicals.

Frontiers in endocrinology
2026

Molecular Insights Into TNF-α and IFN-γ-Induced Epithelial Cell Death in Toxic Epidermal Necrolysis.

Journal of biochemical and molecular toxicology
2026

Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated review.

Expert review of clinical immunology
2026

Cutaneous Toxicities Associated With Amivantamab in Patients With Non-Small Cell Lung Cancer: A Systematic Review.

International journal of dermatology
2026

Uncovering the bactericidal potential of extract and multi-targeting phytochemicals from Mirabilis longiflora L. leaves against multidrug-resistant Pseudomonas aeruginosa and Bacillus cereus.

Scientific reports
2026

Three palladium(II) meso-tetra(pyridyl) porphyrin derivatives for anticancer photodynamic therapy: An in vitro comparative oncology framework in human and canine melanoma.

Journal of photochemistry and photobiology. B, Biology
2026

Quality of Life in Breast Cancer Survivors: A Meta-Analysis of Case-Control Studies.

Psycho-oncology
2026

Microenvironment-responsive EGCG-functionalized nanoplatform for synergistic photothermal-chemotherapy against triple-negative breast cancer.

Nanotechnology
2026

A Novel CSN5 Inhibitor Drives Tumor-Intrinsic PD-L1 Degradation and Exerts Direct Antitumor Efficacy in Triple-Negative Breast Cancer.

Journal of medicinal chemistry
2026

Evaluation of Ginsenosides and Their Derivatives From Panax ginseng as Aromatase Inhibitors for Breast Cancer Treatment-An in silico study.

BioMed research international
2026

CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2026

Dual-phytochemical electrospun PLA-PCL nanofibers loaded withCentella asiaticaextract and curcumin for sustained anticancer and antimicrobial drug delivery.

Biomedical materials (Bristol, England)
2026

Advances in Immunotherapy for Breast Cancer.

Oncology (Williston Park, N.Y.)
2026

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.

Cancer
2026

Partial breast irradiation versus whole breast irradiation after breast-conserving surgery in early-stage breast cancer: a systematic review.

The oncologist
2026

Regulation of CAF by α-Mangostin Promotes the Penetration of Nanomedicine and Inhibits the Metastasis of Breast Tumor.

Molecular pharmaceutics
2026

Emerging mechanisms of microplastic-induced skin diseases: a perspective from the gut-skin axis.

Journal of translational medicine
2026

Toward genomic personalization of breast cancer radiotherapy: foundations, challenges, and a roadmap for clinical integration.

Breast (Edinburgh, Scotland)
2026

Integrative transcriptomic and machine learning framework reveals candidate genes and potential mechanisms of aflatoxin B1 exposure in breast cancer.

Scientific reports
2026

Proton therapy in breast cancer: bridging medical and radiation oncology.

Cancer treatment reviews
2026

High-throughput engineered tumor organoids reveal ROCK signaling as an immunotherapeutic target in triple-negative breast cancer.

Cell reports
2026

Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity.

Basic research in cardiology
2026

Discovery of Novel 1,3,5-trisubstituted-2-thioxo-imidazole Derivatives as Potential Aromatase Inhibitors: Design, Synthesis, In Vitro Anti-Breast Cancer Screening and Molecular Docking Studies.

Drug development research
2026

Beyond Chemotherapy: Network Meta-Analysis Reveals Optimal Neoadjuvant Strategies for Luminal Breast Cancer.

Cancer medicine
2026

The Complement System in ANCA-Associated Vasculitis: Mechanistic Insights, Therapeutic Horizons, and Unmet Clinical Needs.

Immunity, inflammation and disease
2026

Pluronic® F127 Polymeric Micelles as Nanocarriers for Pentamidine: Improving Safety and Biological Efficacy Against Leishmania major.

International journal of molecular sciences
2026

UHPLC-QTOF-MS Profiling of Chemical Constituents in POW9TM Cocktail with Antioxidant and Anti-Proliferative Potentials Against Vero, MCF-7 and MDA-MB-231 Cells.

International journal of molecular sciences
2026

AX-2: A Promising Non-Hemolytic Protein of Bacillus thuringiensis with Potent Selective Cytotoxicity Against Breast Cancer Cells.

Molecules (Basel, Switzerland)
2026

Microparticles against leishmaniasis: Advances, challenges, and perspectives in modified drug delivery systems.

Microbial pathogenesis
2026

Structural reprogramming of irradiated ellagic acid suppresses cell cycle regulators and modulates cytokines via activation of the p53/BAX-CASP3/Bcl-2-cyclin D1 pathway: Validation studies across breast cancer cell lines.

International journal of biological macromolecules
2026

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.

Journal of the European Academy of Dermatology and Venereology : JEADV
2026

Removal of volatile organic compounds by chemical filters significantly inhibited the development of atopic dermatitis symptoms in mice: potential implications for air-conditioning systems in healthcare environments.

Toxicological sciences : an official journal of the Society of Toxicology
2026

First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort.

Cancer immunology, immunotherapy : CII
2026

Cisplatin(IV)-fatty acid prodrug-bound albumin nanoparticles: In vitro, in silico, and in vivo evaluation in breast cancer therapy.

Nanomedicine : nanotechnology, biology, and medicine
2026

Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm.

Lung cancer (Amsterdam, Netherlands)
2026

Molecular docking approaches in mycetoma: Toward improved patient management.

PLoS neglected tropical diseases
2026

An in situ-forming injectable silk hydrogel with a cocktail of chemotherapeutic drugs simultaneously targeting cancer cells and cancer stem cells.

Journal of materials chemistry. B
2026

Biometallic peptide-drug conjugates in photo-crosslinkable hydrogels enable combined photothermal-chemotherapy against breast cancer.

Journal of nanobiotechnology
2026

Injectable hydrogel induces tumor cell extracellular calcification and bone regeneration to disrupt the osteolytic vicious cycle in bone metastasis.

Journal of controlled release : official journal of the Controlled Release Society
2026

Successful Management of Progressive Mycetoma Affecting the Head and Neck.

The American journal of tropical medicine and hygiene
2026

Ultrasmall Platinum Nanoclusters Modulating Dysregulated Reactive Oxide Species and Immunity for Psoriasis Therapy and Prevention.

ACS nano
2026

Green Synthesized Silver Nanoformulation Using Rhubarb Extract for Antibacterial and Anticancer Therapy in Infection-Associated Breast Cancer Mice.

ACS applied materials & interfaces
2026

Tamoxifen-loaded TPGS-PLGA nanoplatform for breast cancer therapy: insights into drug delivery, distribution, treatment efficacy, and ultrasound/photoacoustic imaging.

Nanomedicine (London, England)
2025

Toxic epidermal necrolysis associated with immune checkpoint inhibitors for bladder cancer: A case report.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2025

[Data mining and toxicity profile analysis of immune checkpoint inhibitor-related skin toxicity events based on FAERS].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2026

From Aortitis to Sweet's: The Immune Spectrum of G-CSF Adverse Events.

Seminars in arthritis and rheumatism
2026

Hierarchical pluronic F127-chitosan hydrogel embedding gallium-doxorubicin co-loaded nanocapsules enables dual-responsive release and apoptosis in triple-negative breast cancer cells.

Colloids and surfaces. B, Biointerfaces
2026

Targeted Therapy for CD13-Overexpressing Triple-Negative Breast Cancers Using Apoptosis-Inducing Protein Cage Nanoparticles.

Macromolecular bioscience
2026

Integrating antibody-drug conjugates into the management of early breast cancer.

Cancer treatment reviews
2026

Classification of dermal sensitizers under the globally harmonized system of classification and labelling of chemicals (GHS): A critical review of the principles and current challenges.

Toxicology and industrial health
2026

Triple negative breast cancer: what clinical progress have we seen in the last 5 years?

Expert opinion on investigational drugs
2026

Efficacy of high doses of ivermectin-clorsulon in cattle on Glossina palpalis gambiensis survival and fecundity: implications for human and animal trypanosomoses control.

Parasites & vectors
2026

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial.

Nature communications
2026

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Haematology
2026

Nanoparticle-loaded microneedles as advanced transdermal systems for skin cancer management.

International journal of pharmaceutics
2026

Magnetic hyperthermia's potential in triple-negative breast cancer treatment.

Progress in biophysics and molecular biology
2026

Development of anti-EGFR targeted magnetic nanoparticles for doxorubicin delivery into triple negative breast cancer cells.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
2026

Mechanistic insights into sitagliptin-induced skin autoimmunity: Linking environmental drug exposure to IL-6 activation in bullous pemphigoid.

Ecotoxicology and environmental safety
2026

Glycolysis-dependent sulfur metabolism orchestrates morphological plasticity and virulence in fungi.

eLife
2026

Targeting Hypoxic Tumor Microenvironments: Biocompatible and Stable MPC-BA Micelles in Breast Cancer Treatment.

ACS applied bio materials
2026

Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity.

Current oncology reports
2026

Targeted Neutrophil Extracellular Traps Mimics Combat Staphylococcus aureus Infections.

ACS infectious diseases
2026

Associations of prenatal exposure to organophosphate pesticides with eczema and allergic rhinoconjunctivitis in 4-year-old children: The Japan Environment and Children's Study.

Environmental research
2026

Hidden risks associated with occupational pesticide exposure in women with breast cancer: High frequency of the Luminal B molecular subtype and occurrence of poor prognostic features.

PloS one
2026

Exosome-based strategies and immunotherapy for skin cancer: mechanisms, challenges, and future directions.

Medical oncology (Northwood, London, England)
2026

A multidisciplinary, phased nursing strategy for skin and mucosal management in a pediatric case of toxic epidermal necrolysis with respiratory failure: a case report.

Frontiers in pediatrics
2026

Raspberry protective role in inflammatory diseases: An overview.

Iranian journal of basic medical sciences
2026

Survival and toxicity profile of elderly melanoma patients treated with immune checkpoint inhibitors: a retrospective study from a tertiary care center.

Melanoma research
2026

Derivation of a Point of Departure using NAMs for application in Quantitative Risk Assessment of fragrance materials.

Regulatory toxicology and pharmacology : RTP
2026

An insight into the role of nanotechnology in photothermal and photodynamic therapy of leishmaniasis.

Drug discovery today
2026

Customized Non-invasive Brachytherapy With Tailored Surface Moulds: An Experience From a Tertiary Care Centre.

Clinical oncology (Royal College of Radiologists (Great Britain))
2026

Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING.

Signal transduction and targeted therapy

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Dermatose tóxica.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Dermatose tóxica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Autologous stem cell transplant for severe, progressive juvenile systemic sclerosis.
    Stem cells translational medicine· 2026· PMID 41866801mais citado
  2. Antimicrobial Peptides: Structure, Mechanisms, and Therapeutic Potential in Combating Infectious Diseases.
    Current protein & peptide science· 2026· PMID 41863455mais citado
  3. Erosive pustular dermatosis-like scalp reaction following cranial radiotherapy in a patient with EGFR-mutant NSCLC treated with amivantamab.
    Oncoscience· 2026· PMID 41859195mais citado
  4. Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients Receiving Combination Therapy of Candesartan and Carvedilol for Primary Prevention: A Prospective Longitudinal Study.
    Journal of Korean medical science· 2026· PMID 41844142mais citado
  5. Out of Nucleus: Serine 727 Phosphorylation Orchestrates Non-Canonical STAT3 Functions-Relevance to Triple-Negative Breast Cancer.
    International journal of molecular sciences· 2026· PMID 41828466mais citado
  6. Chemotherapy-Induced Thrombotic Microangiopathy in a Pediatric Patient With a Single Functioning Kidney: A Case Report and Review of the Literature.
    Cureus· 2026· PMID 41994719recente
  7. When Metabolism Recovers but the Brain Does Not: A Case Report of Posterior Reversible Encephalopathy Syndrome (PRES)-Like Encephalopathy After Extreme Metformin-Associated Lactic Acidosis.
    Cureus· 2026· PMID 41994667recente
  8. An information intervention in India reduces consumption of arsenic-contaminated drinking water and has small effects on health.
    PNAS Nexus· 2026· PMID 41994420recente
  9. Multi-Epitope mRNA Vaccine Targeting Dabie Bandavirus Glycoprotein: An Immunoinformatics-Based Study.
    Bioinform Biol Insights· 2026· PMID 41994104recente
  10. Treatment of toxic epidermal necrolysis in a patient with extensive skin damage induced by dimethyl N-cyanodithioiminocarbonate: a case report.
    Front Allergy· 2026· PMID 41993997recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:293815(Orphanet)
  2. MONDO:0017396(MONDO)
  3. GARD:21171(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55787028(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Dermatose tóxica
Compêndio · Raras BR

Dermatose tóxica

ORPHA:293815 · MONDO:0017396
Medicamentos
10 registrados
Início
All ages
MedGen
UMLS
C0458508
Repurposing
1 candidato
hydroxyzineantihistamine
Wikidata
Evidência
🥉 Relato de caso
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades